These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 30682443)

  • 1. Liposomal dexamethasone inhibits tumor growth in an advanced human-mouse hybrid model of multiple myeloma.
    Deshantri AK; Fens MH; Ruiter RWJ; Metselaar JM; Storm G; van Bloois L; Varela-Moreira A; Mandhane SN; Mutis T; Martens ACM; Groen RWJ; Schiffelers RM
    J Control Release; 2019 Feb; 296():232-240. PubMed ID: 30682443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomal delivery of dexamethasone attenuates prostate cancer bone metastatic tumor growth in vivo.
    Kroon J; Buijs JT; van der Horst G; Cheung H; van der Mark M; van Bloois L; Rizzo LY; Lammers T; Pelger RC; Storm G; van der Pluijm G; Metselaar JM
    Prostate; 2015 Jun; 75(8):815-24. PubMed ID: 25663076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
    Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
    Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposomal daunorubicin (DaunoXome) plus dexamethasone for patients with multiple myeloma. A phase II International Oncology Study Group study.
    Mohrbacher AF; Gregory SA; Gabriel DA; Rusk JM; Giles FJ
    Cancer; 2002 May; 94(10):2645-52. PubMed ID: 12173332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PEGylated long-circulating liposomes deliver homoharringtonine to suppress multiple myeloma cancer stem cells.
    Li M; Shi F; Fei X; Wu S; Wu D; Pan M; Luo S; Gu N; Dou J
    Exp Biol Med (Maywood); 2017 May; 242(9):996-1004. PubMed ID: 28056549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposomal drug delivery in an in vitro 3D bone marrow model for multiple myeloma.
    Braham MV; Deshantri AK; Minnema MC; Öner FC; Schiffelers RM; Fens MH; Alblas J
    Int J Nanomedicine; 2018; 13():8105-8118. PubMed ID: 30555229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
    Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF
    Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care.
    Paíno T; Garcia-Gomez A; González-Méndez L; San-Segundo L; Hernández-García S; López-Iglesias AA; Algarín EM; Martín-Sánchez M; Corbacho D; Ortiz-de-Solorzano C; Corchete LA; Gutiérrez NC; Maetos MV; Garayoa M; Ocio EM
    Clin Cancer Res; 2017 Jan; 23(1):225-238. PubMed ID: 27440267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients.
    Hussein MA; Wood L; Hsi E; Srkalovic G; Karam M; Elson P; Bukowski RM
    Cancer; 2002 Nov; 95(10):2160-8. PubMed ID: 12412170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposomal glucocorticoids as tumor-targeted anti-angiogenic nanomedicine in B16 melanoma-bearing mice.
    Banciu M; Metselaar JM; Schiffelers RM; Storm G
    J Steroid Biochem Mol Biol; 2008 Jul; 111(1-2):101-10. PubMed ID: 18602825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanomedicines for the treatment of hematological malignancies.
    Deshantri AK; Varela Moreira A; Ecker V; Mandhane SN; Schiffelers RM; Buchner M; Fens MHAM
    J Control Release; 2018 Oct; 287():194-215. PubMed ID: 30165140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma.
    Hussein MA; Baz R; Srkalovic G; Agrawal N; Suppiah R; Hsi E; Andresen S; Karam MA; Reed J; Faiman B; Kelly M; Walker E
    Mayo Clin Proc; 2006 Jul; 81(7):889-95. PubMed ID: 16835968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modifications to therapy for multiple myeloma: pegylated liposomal Doxorubicin in combination with vincristine, reduced-dose dexamethasone, and thalidomide.
    Hussein MA
    Oncologist; 2003; 8 Suppl 3():39-45. PubMed ID: 14671227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor efficacy of dexamethasone-loaded core-crosslinked polymeric micelles.
    Coimbra M; Rijcken CJ; Stigter M; Hennink WE; Storm G; Schiffelers RM
    J Control Release; 2012 Nov; 163(3):361-7. PubMed ID: 23041274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
    Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
    Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I first-in-man study to investigate the pharmacokinetics and safety of liposomal dexamethasone in patients with progressive multiple myeloma.
    Metselaar J; Lammers T; Boquoi A; Fenk R; Testaquadra F; Schemionek M; Kiessling F; Isfort S; Wilop S; Crysandt M
    Drug Deliv Transl Res; 2023 Apr; 13(4):915-923. PubMed ID: 36592287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective inhibition of matrix metalloproteinase-2 in the multiple myeloma-bone microenvironment.
    Shay G; Tauro M; Loiodice F; Tortorella P; Sullivan DM; Hazlehurst LA; Lynch CC
    Oncotarget; 2017 Jun; 8(26):41827-41840. PubMed ID: 28611279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined treatment with a transforming growth factor beta inhibitor (1D11) and bortezomib improves bone architecture in a mouse model of myeloma-induced bone disease.
    Nyman JS; Merkel AR; Uppuganti S; Nayak B; Rowland B; Makowski AJ; Oyajobi BO; Sterling JA
    Bone; 2016 Oct; 91():81-91. PubMed ID: 27423464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal prednisolone inhibits tumor growth in a spontaneous mouse mammary carcinoma model.
    Deshantri AK; Kooijmans SA; Kuijpers SA; Coimbra M; Hoeppener A; Storm G; Fens MH; Schiffelers RM
    J Control Release; 2016 Dec; 243():243-249. PubMed ID: 27773734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity.
    Shahin M; Soudy R; Aliabadi HM; Kneteman N; Kaur K; Lavasanifar A
    Biomaterials; 2013 May; 34(16):4089-4097. PubMed ID: 23465829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.